Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with B / Bepotastine 		 
Bepotastine
  

Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion®. It is currently undergoing trials in the U.S.
BrandsTalion
CategoriesAnti-Allergic Agents
Antihistamines
Histamine H1 Antagonists, Non-Sedating
ManufacturersIsta pharmaceuticals
PackagersI
h
SynonymsBepotastine besilate
Betotastine besilate
TAU-284DS

indication

For the treatment of allergic conjunctivitis and uriticaria/puritus.

pharmacology

Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. It has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. Bepotastine is under investigation in an eye drop formulation by Ista for the treatment of allergic conjunctivitis. An oral formulation of this drug is approved in Japan for the treatment of allergic conjunctivitis and uriticaria/puritus. Ista Pharm. filed an IND with the FDA for bepotastine in December of 2006.

mechanism of action

Bepotastine has three primary mechanisms of action. It is a non-sedating, selective antagonist of the histamine 1 (H1) receptor, it has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues.

absorption

High oral absorption

Terms of Use